FindMyKOL

Douglas Goodin

Basic profile

University of California, San Francisco

ORCIDOn fileNPIOn fileSign in to see identifiers
✓ Itemized record
RegionSan Francisco, CA · WestSpecialtyNeurologyFocusNeurology
Active KOLFindMyKOL type: NationalLatest publication2021Online presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Douglas Goodin is a Neurology physician affiliated with University of California, San Francisco. OpenAlex indexes 251 publications with 17,658 citations (h-index 68). By OpenAlex citation count, this profile ranks in the top 10% of Neurology profiles in the FindMyKOL directory.

Overview

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
251publications

Publications indexed by OpenAlex, matched via ORCID. Counts exclude supporting files.

17,658citations

Citations across these publications.

68h-index

H-index from these publications.

Clinical & industry

trials, payments and federal funding
11companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓

Industry payments

11 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

  • Amgen Inc.
    Program year202518 payments
    $16,736
  • Novartis Pharmaceuticals Corporation
    Program year20253 payments
    $89
  • Genentech, Inc.
    Program year20251 payment
    $48
All 29 payment records: search, sort and filter.Explore →

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.

Medicare prescribing footprint (2023)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Nervous system

    51%
    Gabapentinoids18.9%
    Gabapentin81%Pregabalin19%
    Part D<11 patients
    Potassium Channel Blocker7.5%
    Dalfampridine Er100%
    Part D≥13 patients

    + 7 more classes in this area

  • Cancer & immunology

    33.1%
    Other immunostimulants15.7%
    Copaxone68%Glatopa32%
    Part D<11 patients
    Sphingosine 1-phosphate Receptor Modulator10.8%
    Fingolimod59%Mayzent41%
    Part D<11 patients

    + 2 more classes in this area

  • Musculoskeletal

    13.4%
    gamma-Aminobutyric Acid-ergic Agonist13.4%
    Baclofen100%
    Part D≥20 patients
Where care is delivered (Part B)0% facility · 100% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Publications

Matched to this physician's OpenAlex author record; most-cited works shown first.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”